CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Endpoints News
Original article

Pathos does deals with AstraZeneca, China's Alphamab, seeks up to $300M Series E

PartnershipAlphamabPositive
AI Analysis

Summary

Pathos AI signed a major antibody-drug conjugate deal with Chinese biotech Alphamab and partnered with AstraZeneca, while seeking up to $300M in Series E funding.

Importance:7/10
Sentiment:
0.70
partnershipADCSeries E fundingAstraZenecaChinaantibody-drug conjugate
Related Companies

Read the original article

Published by Endpoints News on August 4, 2026 12:00 AM

Read Original